D
Deleted member 13588
Silver
- Joined
- Apr 17, 2021
- Posts
- 697
- Reputation
- 691
So I've been watching one of Kevin Mann's hairloss videos where he talks about a substance called KY19382. This substance supposedly affects (activates) the WNT pathway and is being researched as a potential hair growth stimulant, but also has another interesting mechanism of action...
At 6:45 he cites a study:
KY19382 is one of the newly synthesized analogues of indirubin‐3′‐monoxime (I3O), a glycogen synthase kinase‐3β (GSK‐3β) inhibitor, and has a significant ability to activate Wnt/β‐catenin signalling (Choi et al., 2019). Indirubin is an active ingredient of the indigo plant, Danggui Longhui Wan, used as traditional anti‐leukaemia medicine (Xiao et al., 2002). I3O is known to be a Wnt/β‐catenin activator that stabilizes β‐catenin via inhibition of GSK‐3β and has been shown to accelerate bone growth and inhibit adipogenesis (Cha & Choi, 2014; Choi et al., 2014; Zahoor et al., 2014). Furthermore, we recently found that KY19382 elongated tibial length by inactivating GSK‐3β and blocking the binding of CXXC‐type zinc finger protein 5 (CXXC5) and dishevelled (Dvl) (Choi et al., 2019). Moreover, PTD‐DBM, a peptide that interferes with CXXC5–Dvl interaction via binding to the PDZ domain of Dvl, stimulated wound‐induced hair follicle neogenesis (WIHN) and hair regrowth (Lee et al., 2017). However, this peptide is limited for routine application due to its cost and stability.
sources:
KY19382, a novel activator of Wnt/β‐catenin signalling, promotes hair regrowth and hair follicle neogenesis
The promotion of hair regeneration and growth heavily depends on the activation of Wnt/β‐catenin signalling in the hair follicle, including dermal papilla (DP). KY19382, one of the newly synthesized analogues of indirubin‐3′‐monoxime ...www.ncbi.nlm.nih.gov
Could this be it? A potential medicinal substance für shortcels?
Last edited:
